The SWI/SNF complex is mutated in 20–25% of human cancers [119], and mechanistically, the loss of SNF5 tumor suppression, which has been identified in several cancers including chronic myeloid leukemia, malignant rhabdoid and central nervous system tumors, induces EZH2 gene expression, and PRC2 target genes are broadly H3K27-trimethylated [122]. This evidence concerns the gene SMARCA1 and cancer.